iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 2,500 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the business’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $87.88, for a total transaction of $219,700.00. Following the completion of the sale, the chief executive officer owned 2,172,500 shares of the company’s stock, valued at approximately $190,919,300. This represents a 0.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Performance

NASDAQ:IRMD opened at $90.40 on Thursday. iRadimed Corporation has a one year low of $50.88 and a one year high of $107.90. The firm has a market cap of $1.16 billion, a P/E ratio of 49.40 and a beta of 0.90. The firm has a 50-day simple moving average of $93.03 and a 200-day simple moving average of $95.01.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating the consensus estimate of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The business had revenue of $21.98 million during the quarter, compared to analyst estimates of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, research analysts predict that iRadimed Corporation will post 1.52 EPS for the current fiscal year.

iRadimed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, May 15th. iRadimed’s payout ratio is 43.72%.

Institutional Trading of iRadimed

Hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its holdings in iRadimed by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock worth $6,848,000 after buying an additional 33,072 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in iRadimed during the third quarter worth $422,000. Tudor Investment Corp ET AL purchased a new stake in iRadimed during the third quarter worth $666,000. RFG Advisory LLC purchased a new stake in iRadimed during the fourth quarter worth $1,594,000. Finally, Baader Bank Aktiengesellschaft purchased a new stake in iRadimed during the fourth quarter worth $595,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on IRMD shares. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Lake Street Capital reaffirmed a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a report on Wednesday, February 11th. Roth Mkm reaffirmed a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a report on Tuesday, February 10th. Finally, Weiss Ratings raised shares of iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.